Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Regorafenib versus lomustine for relapsed glioblastoma

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 862

Dr Giuseppe Lombardi - Istituto Oncologico Veneto, Padova, Italy

Dr Lombardi talks with ecancer at the ESMO 2017 Congress about the randomised, phase II REGOMA trial evaluating regorafenib versus lomustine in relapsed glioblastoma patients.

He outlines that the primary endpoint for the study, overall survival, was met with patients treated with regorafenib having statistically longer overall survival compared to the patients treated with lomustine. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence